STAT+: Pharmalittle: Novavax faces raw-materials shortages for Covid-19 shot; India curbs vaccine exports
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest. We hope to catch up on some reading, hang with a short person or two, and promenade with the official mascot. We will also stop to observe some ancient, but meaningful, rituals. And what about you? This is a fine time to consider a little spring cleaning, or enjoy the great outdoors. You could putter around your castle or try to make that appointment for a vaccine. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …
Novavax (NVAX) is delaying signing a contract to supply its Covid-19 vaccine to the European Union because the company is struggling to source some raw materials, according to Reuters. Prolonging the talks with the EU might further complicate vaccination plans, as the bloc had planned to sign a deal early this year for at least 100 million doses of the vaccine, with an option for another 100 million. Novavax has eight manufacturing locations, including the Serum Institute of India, the world’s biggest vaccine maker.
Continue to STAT+ to read the full story…
